Fate Therapeutics Inc

Healthcare · Biotechnology

2.10$ -0.9% vs. previous close Closing price · As of: Oct 8, 2026

Statements

Balance Sheet

Fate Therapeutics Inc (FATE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 260 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet FATE
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	49	95	85	74	73	105	93	83	220	213	221	200	340	302	322	654	626	622	1,046	1,016	985	921	858	807	749	706	630	585	544	506	570	529	495	441	399	372	344	319	285	260
Current Assets	47	93	83	72	70	103	91	80	214	205	186	165	306	227	208	540	497	494	804	713	694	633	599	599	535	502	438	392	364	332	394	319	310	292	248	230	221	209	180	158
Cash	37	89	41	31	43	89	33	36	183	191	183	71	250	100	83	433	349	167	106	77	129	134	65	55	82	61	42	47	33	42	121	37	38	36	45	41	41	47	40	32
Cash & Short-Term Investments	47	92	82	71	69	101	89	78	211	201	183	162	303	221	203	533	489	483	790	696	679	616	574	569	505	436	409	378	350	315	384	305	297	279	240	223	215	204	175	154
Receivables	–	–	–	–	–	–	0.5	–	0.5	0.5	0.5	1.7	1.5	0.0	1.2	1.7	3.2	5.5	6.9	10	7.3	8.7	14	13	10	38	14	2.8	1.5	1.8	0.9	1.0	4.1	3.5	2.4	1.4	0.7	0.9	0.7	0.7
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	-1.7	-1.5	–	-1.2	–	0.0	0.0	–	–	0.0	–	–	–	–	0.0	–	–	0.0	–	–	-12	–	–	–	–	–	–	–	–
Property, Plant & Equipment	1.8	1.6	1.7	1.9	2.5	2.6	2.6	2.9	3.8	5.1	8.4	9.2	9.7	11	12	16	21	32	48	125	75	162	98	103	109	176	109	170	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	24	22	21	19	27	28	28	31	46	53	75	72	72	58	103	179	202	238	256	264	254	243	225	227	231	222	153	147	141	138	144	132	133	122	110	110	110	112	105	107
Current Liabilities	15	15	17	8.1	9.7	11	13	16	23	27	29	29	41	28	25	45	54	86	95	106	92	81	78	92	104	114	49	45	41	39	45	35	37	39	28	29	28	36	31	33
Short-Term Debt	8.0	8.2	7.6	6.7	15	7.3	0.8	2.0	3.3	2.4	6.3	8.6	17	1.7	1.9	2.4	2.3	3.4	4.4	5.1	4.7	5.6	5.6	5.7	5.8	5.6	5.5	5.8	6.0	6.2	6.4	6.6	6.9	7.4	6.5	5.7	4.8	4.6	4.7	4.9
Accounts Payable	1.2	0.9	2.5	1.2	2.2	1.7	2.2	3.5	5.2	4.2	5.4	5.4	5.7	5.8	5.2	14	3.7	6.3	9.0	5.8	6.4	8.6	11	8.4	9.6	8.3	9.9	7.5	5.7	4.7	6.8	5.5	6.3	9.4	4.2	4.0	3.5	2.7	3.3	3.3
Long-Term Debt	4.6	2.5	1.1	6.7	15	15	14	13	12	12	11	9.5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	25	73	64	55	46	77	65	52	174	160	146	128	268	245	219	474	424	384	790	752	730	679	633	580	518	484	477	438	403	368	426	397	362	319	288	261	234	207	180	153
Retained Earnings	-168	-176	-186	-196	-206	-219	-233	-253	-269	-285	-305	-329	-355	-384	-417	-445	-504	-557	-602	-657	-700	-769	-835	-911	-994	-1,051	-1,070	-1,122	-1,168	-1,212	-1,260	-1,298	-1,346	-1,398	-1,436	-1,470	-1,502	-1,534	-1,566	-1,596
Shares Outstanding	32	37	41	41	41	44	53	53	54	65	65	65	67	76	76	79	87	87	93	94	95	96	96	97	97	97	98	98	99	99	101	117	118	118	118	119	119	119	120	120

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings